[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Pathways Plc ADR (CMPS)

Compass Pathways Plc ADR (CMPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

COMPASS Pathways Reports Before Its FDA Timeline Becomes More Than a Projection

COMPASS Pathways (CMPS) reports Q2 2026 earnings on July 30, 2026, with analysts expecting a loss of $0.46 per share. The mental health biotech, focused on its investigational COMP360 psilocybin treatment for treatment-resistant depression, faces a critical test as investors assess progress in its Phase III program and cash runway. With the stock trading at $10.90 and analysts maintaining overwhelmingly bullish ratings despite recent volatility, this report will determine whether the company can sustain momentum following last quarter's strong beat.

COMPASS Pathways is a mental health biotech company developing COMP360, a pharmaceutical-grade psilocybin formulation for treatment-resistant depression (TRD). The company is advancing a Phase III...

Fundamentals

See More
  • Market Capitalization, $K 1,470,944
  • Shares Outstanding, K 134,949
  • Annual Sales, $ 0 K
  • Annual Income, $ -287,860 K
  • EBIT $ -172 M
  • EBITDA $ -172 M
  • 60-Month Beta 2.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.28

Options Overview Details

View History
  • Implied Volatility 93.91% (-12.00%)
  • Historical Volatility 65.65%
  • IV Percentile 30%
  • IV Rank 14.11%
  • IV High 232.72% on 02/10/26
  • IV Low 71.12% on 05/14/26
  • Expected Move (DTE 22) 1.87 (16.95%)
  • Put/Call Vol Ratio 0.43
  • Today's Volume 123
  • Volume Avg (30-Day) 4,662
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 133,365
  • Open Int (30-Day) 132,228
  • Expected Range 9.16 to 12.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.46
  • Number of Estimates 6
  • High Estimate $-0.31
  • Low Estimate $-0.70
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.59 +5.57%
on 07/28/26
14.60 -23.42%
on 07/16/26
-2.97 (-20.99%)
since 06/30/26
3-Month
8.76 +27.63%
on 05/01/26
15.40 -27.40%
on 06/29/26
+2.12 (+23.40%)
since 04/30/26
52-Week
3.92 +184.95%
on 07/31/25
15.40 -27.40%
on 06/29/26
+7.24 (+183.76%)
since 07/30/25

Most Recent Stories

More News
COMPASS Pathways Reports Before Its FDA Timeline Becomes More Than a Projection

Barchart Research What to Expect from CMPS Earnings CMPS Generated July 29, 2026 Current Price $10.90 EPS Estimate $$-0.46 Consensus Rating Strong Buy Average Move 10.06% COMPASS Pathways Reports Before...

CMPS : 11.19 (+2.66%)
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

Compass Management will host a conference call at 8:00 am ET (1:00 pm UK)

CMPS : 11.19 (+2.66%)
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

HELP : 8.02 (+1.39%)
CMPS : 11.19 (+2.66%)
ATAI : 7.20 (+0.28%)
JNJ : 255.67 (-3.71%)
LLY : 1,157.99 (-4.30%)
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy

Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct...

CMPS : 11.19 (+2.66%)
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

New 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable...

CMPS : 11.19 (+2.66%)
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...

CMPS : 11.19 (+2.66%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 8.02 (+1.39%)
CMPS : 11.19 (+2.66%)
GHRS : 28.13 (+0.54%)
JNJ : 255.67 (-3.71%)
DFTX : 43.80 (+3.89%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 8.02 (+1.39%)
CMPS : 11.19 (+2.66%)
GHRS : 28.13 (+0.54%)
JNJ : 255.67 (-3.71%)
DFTX : 43.80 (+3.89%)
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment...

CMPS : 11.19 (+2.66%)
KLRA : 17.09 (+1.24%)
SPRO : 1.1950 (+0.42%)
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...

CMPS : 11.19 (+2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK.

See More

Key Turning Points

3rd Resistance Point 11.68
2nd Resistance Point 11.43
1st Resistance Point 11.16
Last Price 11.19
1st Support Level 10.64
2nd Support Level 10.39
3rd Support Level 10.12

See More

52-Week High 15.40
Last Price 11.19
Fibonacci 61.8% 11.02
Fibonacci 50% 9.66
Fibonacci 38.2% 8.31
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.